Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and BMS-986205 in first-line recurrent/metastatic head and neck cancer
NCT03386838Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linrodostat in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Bristol Myers Squibb. Planned start Mar 2018; status: withdrawn.
02
Drugs
linrodostat
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03386838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386838.